 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || BOL-DP-o-04 / BOL Pharma
Trial completion, Trial completion date, Trial primary completion date: BOL-DP-o-04 in Patients With Low Back Pain and Sciatica (clinicaltrials.gov) - Dec 8, 2022
P1/2, N=26, Completed, Sponsor: Breath of Life International Pharma Ltd
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
- ||| BOL-DP-o-04 / BOL Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: BOL-DP-o-04 in Patients With Low Back Pain and Sciatica (clinicaltrials.gov) - Sep 2, 2021
P1/2, N=26, Active, not recruiting, Sponsor: Breath of Life International Pharma Ltd
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022 Recruiting --> Active, not recruiting | N=150 --> 26 | Trial completion date: Nov 2020 --> Dec 2021 | Trial primary completion date: Nov 2020 --> Dec 2021
- BOL-DP-o-04 / BOL Pharma
[VIRTUAL] EXPLORATORY STUDY TO ASSESS THE SAFETY OF SUBLINGUAL OIL BASED MEDICAL CANNABIS BOL-DP-O-04 IN DIALYSIS PATIENTS WHO HAVE CHRONIC PAIN () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1247;
Conclusions Overall, sublingual oil based medical cannabis appeared to be safe and well tolerated in hemodialysis patients as long as treatment is performed under close medical supervision and carful titration. This data supports further clinical development.
- | BOL-DP-o-04 / BOL Pharma
Enrollment change, Trial termination: Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy (clinicaltrials.gov) - Mar 24, 2021
P2a, N=2, Terminated, Sponsor: Breath of Life International Pharma Ltd
This data supports further clinical development. N=100 --> 2 | Recruiting --> Terminated; study stopped due to company strategic prioritization
- |||| BOL-DP-o-04 / BOL Pharma
New P1/2 trial: BOL-DP-o-04 in Patients With Low Back Pain and Sciatica (clinicaltrials.gov) - Nov 4, 2019
P1/2, N=150, Recruiting, Sponsor: Breath of Life International Pharma Ltd
- | BOL-DP-o-04 / BOL Pharma
Trial completion date, Trial primary completion date: Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy (clinicaltrials.gov) - Oct 1, 2019
P2a, N=100, Recruiting, Sponsor: Breath of Life International Pharma Ltd
N=100 --> 2 | Recruiting --> Terminated; study stopped due to company strategic prioritization Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Dec 2020
- | BOL-DP-o-04 / BOL Pharma
New P2a trial: Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy (clinicaltrials.gov) - Sep 9, 2019
P2a, N=100, Recruiting, Sponsor: Breath of Life International Pharma Ltd